Why the study?
Physical health monitoring for patients prescribed antipsychotics is substandard, contributing to premature death from preventable cardiometabolic disease.
Does a pharmacist-led multidisciplinary intervention improve adherence to cardiometabolic monitoring guidelines in patients prescribed oral antipsychotics compared to usual care?
Does a pharmacist-led multidisciplinary intervention improve adherence to cardiometabolic monitoring guidelines in patients prescribed oral antipsychotics compared to usual care?
A pharmacist-led multidisciplinary intervention in general practice significantly improves adherence to cardiometabolic monitoring guidelines for patients on antipsychotics.
Answers are grounded in this paper and cite their sources.
GPCP-led monitoring may improve cardiometabolic checks in antipsychotic users; leaves open efficacy in randomized trials.
BACKGROUND: People with severe mental health illness die prematurely, often due to preventable cardiometabolic disease, which can be exacerbated by antipsychotic medicines that are effective for treating mental illness. Literature demonstrates that physical health monitoring, as recommended in guidelines, for people receiving antipsychotics is substandard. Therefore, we aimed to scope the potential of a general practice clinical pharmacist (GPCP)-led multidisciplinary intervention optimising adherence to cardiometabolic monitoring guidelines and delivering polypharmacy reviews. METHOD: Prospective intervention scoping study in three urban general practices; one usual care, two intervention. Patients 18-65 years old prescribed oral antipsychotics were identified from records, and invited for cardiometabolic monitoring and GPCP medication review, from January to December 2022. Interventions and onward referrals were recorded and collated. Anonymised pre- and post-review data were analysed, and actions were graded for clinical importance. RESULTS: In total 1.5% (210/14,159) of patients aged 18-65 years met inclusion criteria; usual care practice (n = 58); and intervention practices (n = 152). From baseline, the usual care practice achieved an absolute 7% increase in the cardiometabolic monitoring care bundle (glucose/glycosylated haemoglobin, lipids, blood pressure plus body mass index) versus 19-58% in the intervention practices. Two-thirds (92/152) of patients participated in medication reviews, requiring pharmacological and/or non-pharmacological clinical actions. The majority of actions were graded as moderate importance. Seven percentage of patients were identified as new pre-diabetic/diabetic and 6% were at high risk of cardiovascular disease requiring statin initiation. CONCLUSION: A pharmacist-led multidisciplinary general practice-based approach may be effective at optimising cardiometabolic monitoring; identifying and treating diabetic and cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: